Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedCap ABCHIX:MCAPS 93 ROE % is 15.02% as of Mar. 2026, which is 0% below its 10-year median of 15.05. GuruFocus rates CHIX:MCAPS with a GF Score™ of 93/100 and a GF Value™ of kr596.05 (Fairly Valued). Among 799 Medical Devices & Instruments companies, MedCap AB ranks better than 87.23% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. MedCap AB's annualized net income for the quarter that ended in Mar. 2026 was kr224 Mil. MedCap AB's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was kr1,489 Mil. Therefore, MedCap AB's annualized ROE % for the quarter that ended in Mar. 2026 was 15.02%.
The historical rank and industry rank for MedCap AB's ROE % or its related term are showing as below:
CHIX:MCAPs'
s ROE % Range Over the Past 10 Years
Min: 0.03 Med: 15.05 Max: 18.33
Current: 16
During the past 13 years, MedCap AB's highest ROE % was 18.33%. The lowest was 0.03%. And the median was 15.05%.
CHIX:MCAPs's ROE % is ranked better than 87.23% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.54
vs CHIX:MCAPs: 16.00
MedCap AB (CHIX:MCAPs) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
MedCap AB ROE % Related Terms
MedCap AB ROE % Historical Data
* Premium members only.
The historical data trend for MedCap AB's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, MedCap AB's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedCap AB ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's ROE % distribution charts can be found below:
* The bar in red indicates where MedCap AB's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
MedCap AB (CHIX:MCAPS) has a ROE % of 15.02% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on MedCap AB and its competitors. This is near median its historical median of 15.05. Over the past decade, MedCap AB's ROE % has ranged from 0.03 to 18.33. According to the industry distribution chart, MedCap AB ranks #102 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 12.8%.
Is MedCap AB's ROE % too high?
MedCap AB's current ROE % of 15.02% is near median its 10-year median of 15.05. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 18.33. The Medical Devices & Instruments industry median ROE % is 2.54. MedCap AB's value of 15.02% is 491.3% above this industry median. Based on the distribution chart, MedCap AB ranks #102 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, MedCap AB has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MedCap AB ranks #102 out of 799 companies for ROE %. This places MedCap AB in the top 13% of its industry — outperforming the majority of peers. The industry median ROE % is 2.54. MedCap AB's value of 15.02% is 491.3% above this benchmark. Historically, MedCap AB's own ROE % has ranged from 0.03 to 18.33 over the past decade. While the company's 10-year median is 15.05 vs. the industry median of 2.54, MedCap AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.54, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedCap AB's current ROE % of 15.02% is 491.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on MedCap AB and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedCap AB's current ROE % is 15.02%, which is near median its own 10-year median of 15.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (CHIX:MCAPS) is currently considered Fairly Valued. The stock's GF Value™ is kr596.05, compared to a current price of kr555.00 — trading 6.9% below its estimated fair value. The current ROE % is 15.02%, which is near median its 10-year median of 15.05 and 491.3% above the Medical Devices & Instruments industry median of 2.54. MedCap AB's overall GF Score™ is 93/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For MedCap AB (CHIX:MCAPS), the current ROE % is 15.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedCap AB (CHIX:MCAPS) Overvalued in 2026?
Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued.
The current stock price of kr555.00 is trading 6.9% below its estimated GF Value™ of kr596.05.
GuruFocus considers MedCap AB to be Fairly Valued.
Key valuation signals for CHIX:MCAPS:
ROE %: 15.02% (near median its 10-year median of 15.05)
GF Value™: kr596.05 vs. price of kr555.00 (6.9% below fair value)
Industry Position: 491.3% above the Medical Devices & Instruments median (#102 of 799)
No single metric tells the full story. See the CHIX:MCAPS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.
93GF Score
Get the complete analysis for CHIX:MCAPS
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:MCAPS has been successfully added to your 
